secwatch.observer — SEC 8-K summary
======================================

Issuer:     TransMedics Group, Inc. (TMDX)
CIK:        0001756262
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0000950170-25-029071
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransMedics Q4 revenue $121.6M (+50% YoY); full year net income $35.5M; 2025 guidance $530-552M
--------------------------------------------------------------------------------

- Q4 revenue $121.6M (+50% YoY); net income $6.9M ($0.19 EPS); full year revenue $441.5M (+83% YoY).
- Full year net income $35.5M ($1.01 EPS) vs net loss $25.0M in 2023; 2025 revenue guidance $530-552M (20-25% growth).
- U.S. OCS cases 3,715 in 2024 (+58% YoY); overall OCS market share 20.9% (up from 13.8% in 2023).
- Independent review found no misconduct after short report allegations; submitted response to FDA Citizen Petition.
- Gross margin 59.4% full year, down from 63.8% due to higher service revenue mix; cash $336.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1756262/000095017025029071/0000950170-25-029071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1756262/000095017025029071/tmdx-20250227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-029071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer